Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

IgG4-related Castleman disease: clinical-pathological features and therapeutic implications.

Created on 10 Nov 2026

Authors

Jasmin Mahajne, Lucia Bongiovanni, Andres Gonzalez Garcia, Maria Pilar Iranzo Alcolea, Marco Lanzillotta, Teresa Calimeri, Federico Erbella, Andres J M Ferreri, Lorenzo Dagna, Maurilio Ponzoni, Emanuel Della-Torre

Published in

Clinical and experimental rheumatology. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

IgG4-related disease (IgG4-RD) and idiopathic multicentric Castleman disease (iMCD) are considered mutually exclusive. A clinical entity with features of IgG4-RD and iMCD has been named IgG4-related Castleman disease (IgG4-CD) but remains poorly characterised. We here describe demographic, clinical, histological characteristics of IgG4-CD, its prognosis and response to immunosuppressive treatment.
This retrospective study included patients with IgG4-RD and iMCD referred to San Raffaele Hospital (Milan, Italy) and Ramón y Cajal Hospital (Madrid, Spain). IgG4-CD was defined based on fulfillment of international diagnostic criteria for CD and IgG4-RD. Demographics, epidemiological, clinical, serological data, pathological findings and treatment outcomes were recorded. Results were compared with IgG4-RD and iMCD patients.
Eight patients with a median age of 63 years (range 49-71) at the time of IgG4-CD diagnosis were included. All presented with constitutional symptoms. All lymph node biopsies showed high-grade plasmocytosis and features of CD. IgG4-CD extranodal involvement included salivary and lacrimal glands, pancreas, and bile ducts. Lymph nodes were more frequently involved in IgG4-CD than in IgG4-RD, serum IgG4 were higher in IgG4-CD than in IgG4-RD and iMCD, C-reactive protein in IgG4-CD was lower than in iMCD (p<0.0001). Erythrocyte sedimentation rate (ESR) was higher in IgG4-CD than in IgG4-RD (p=0.0334). All patients responded to glucocorticoids or second-line therapy with rituximab with a favourable outcome at the longest available follow-up.
IgG4-CD is characterised by constitutional symptoms, elevated ESR and IgG4 levels, and high-grade lymph node plasmacytosis. Good response to anti-CD20 therapy and a favourable prognosis mark a difference with iMCD.

PMID:
43006875
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement